deutsche bank is stepping to the sidelines on cvs health stock warning of potential risks to earnings for the next couple years analyst george hill downgraded his rating on shares of the healthcare business to hold from buy he has multiple reasons for the move including risks related to cvs’s liability in ongoing opioid litigation and changes affecting its pharmacy segment cvs ticker cvs is a beneficiary of the 340b program which requires manufacturers like novartis nvs to sell certain drugs at a discounted price